Mark Rothera joins Silence Therapeutics as new CEO
14th Sep 2020 13:14
(Sharecast News) - Drug discovery and development company Silence Therapeutics announced the appointment of Mark Rothera as its president and chief executive officer and board member on Monday, effective immediately.
Read moreSilence Therapeutics makes 'exceptional' year-to-date progress
23rd Jun 2020 10:14
(Sharecast News) - RNA therapeutics developer Silence Therapeutics said on Tuesday that it had continued to make "exceptional progress" in securing additional high-value partnerships and advancing its proprietary pipeline year-to-date.
Read moreDirector dealings: Silence Therapeutics CFO lowers stake
12th May 2020 15:45
(Sharecast News) - Silence Therapeutics revealed on Tuesday that chief financial officer Rob Quinn had offloaded of 89,054 ordinary shares in the AIM-listed biotechnology group.
Read moreSilence Therapteutics inks deal with Takeda after decent year
7th Jan 2020 15:43
(Sharecast News) - Serious disease therapeutics developer Silence Therapeutics updated the market on the year ended 31 December on Tuesday, reporting that it has entered into a technology evaluation agreement with Takeda to explore the potential of using its platform to generate siRNA molecules against a novel, undisclosed target discovered by Takeda.
Read moreSilence Therapeutics elevates Iain Ross to executive chairman
17th Dec 2019 13:50
(Sharecast News) - Silence Therapeutics announced a "strengthening" of its board and management team on Tuesday, with Iain Ross set to be appointed as executive chairman from 1 January.
Read moreSilence Therapeutics to launch new trial before year end
12th Sep 2019 09:15
(Sharecast News) - Silence Therapeutics said on Thursday that the first half of the year saw good progress in the development of its lead candidate, SLN124, with the first patient set to be dosed before the year is out.
Read moreSilence Therapeutics enters into collaboration with Genomics England
28th May 2019 13:26
(Sharecast News) - Novel therapeutics developer Silence Therapeutics has entered into a collaboration with Genomics England for the investigation of novel targets involved in human disease, it announced on Tuesday.
Read moreSilence Therapeutics makes Rob Quinn permanent CFO
18th Apr 2019 09:27
(Sharecast News) - Biotechnology company Silence Therapeutics said it had appointed Rob Quinn to take over as its full-time chief financial officer, effective immediately.
Read moreSilence Therapeutics losses widen as it progresses drug candidates
11th Mar 2019 10:36
(Sharecast News) - Drug development company Silence Therapeutics announced its unaudited preliminary results for the year ended 31 December on Monday, reporting a loss after tax of £18.4m, widening form £1.6m a year earlier.
Read moreSilence Therapeutics CFO steps down
9th Jan 2019 10:40
(Sharecast News) - Silence Therapeutics chief financial officer David Ellam stepped down from the group with immediate effect on Wednesday.
Read moreSilence Therapeutics losses deepen as lead drugs near trials
11th Sep 2018 12:44
(Sharecast News) - Biotechnology firm Silence Therapeutics shares fell on Tuesday after reporting a first half loss after tax of £8.7m, up 57%, due to costs associated with bringing its two lead programmes towards the clinic.
Read moreSilence confirms minority stake in Arrowhead Pharmaceuticals
13th Jan 2017 14:19
(ShareCast News) - Discoverer, deliverer and developer of novel RNA therapeutics for the treatment of serious diseases, Silence Therapeutics updated the market on its announcement on 9 January regarding the acquisition of a minority stake in Arrowhead Pharmaceuticals. The AIM-traded company said it
Read moreSilence Therapeutics buys stake in US-based Arrowhead Parma
9th Jan 2017 08:18
(ShareCast News) - Silence Therapeutics, a developer of ribonucleic acid (RNA) treatments, has bought an 8.4% stake in Nasdaq-listed Arrowowhead Pharmaceuticals for $7.8m ($9.6m). The AIM-listed company bought the minority stake, which represents about 6m shares in the US pharmaceutical's share c
Read moreSilence Therapeutics, Quark Pharmaceuticals reach settlement
20th Dec 2016 12:13
(ShareCast News) - Silence Therapeutics said it has reached a settlement in the arbitration process with Quark Pharmaceuticals, with the former to receive a $1m cash payment. Under the terms of the agreement, AIM-listed Silence was also eligible to receive either about 2% royalties from Quark plus m
Read moreNew Serco CEO Soames marks arrival with large share purchase
6th May 2014 15:51
Rupert Soames, who last week took up the role of Chief Executive Officer at embattled Serco Group, has given a show of faith in his own leadership - and taken advantage of the latest dip in its share price - with the purchase of 242,000 shares at 354.30p a share. The £857,406 deal gives a show of f
Read more